Daptomycin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Daptomycin: From Gram-Positive Bacterial Infections to Osteoarthritis
One-Sentence Summary
Daptomycin is a cyclic lipopeptide antibiotic originally used to treat serious Gram-positive bacterial infections (complicated skin/skin-structure infections, S. aureus bacteraemia, right-sided infective endocarditis). The TxGNN model predicts it may be effective for Osteoarthritis, with 0 clinical trials and 10 publications currently associated with this signal — however, closer review shows the literature actually concerns treatment of prosthetic joint/osteoarticular infections in patients who happen to have osteoarthritis, not treatment of osteoarthritis itself. This appears to be a keyword-confusion artifact rather than a genuine repurposing signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gram-positive bacterial infections (complicated skin/skin-structure infections, S. aureus bacteraemia, right-sided infective endocarditis) — Finland-specific label text unavailable (drug not marketed there) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L4 |
| Finland Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (original_moa: [Data Gap]). Based on generally known pharmacology (and consistent with statements found within the literature retrieved for this pack, e.g. PMID 39571268), daptomycin is a calcium-dependent cyclic lipopeptide that disrupts the cell membrane of Gram-positive bacteria, causing rapid depolarization and cell death. It is not known to have a specific mechanistic link to degenerative joint disease.
The high TxGNN score for osteoarthritis does not appear to reflect a genuine pharmacological relationship. All ten retrieved publications describe daptomycin's use in treating prosthetic joint infections (PJI) or other osteoarticular infections — serious complications that can occur after joint replacement surgery, which patients often undergo because of osteoarthritis. In other words, the literature co-occurrence is driven by shared vocabulary ("joint," "osteoarticular," patients with an OA history) rather than any evidence that daptomycin treats osteoarthritis itself. None of the studies test daptomycin as a disease-modifying or symptomatic therapy for OA.
For context, the model's second-ranked prediction — rheumatoid arthritis (score 99.84%, rank 2176) — is supported by more mechanistically direct, if still early-stage, evidence: two 2025 preclinical studies (PMID 39571268, PMID 40923559) report that daptomycin and its lipopeptide derivatives suppress inflammatory cytokines and NF-κB signalling in a collagen-induced arthritis mouse model, suggesting a possible independent anti-inflammatory activity distinct from its antibacterial action. This is not yet human evidence, but it is a more biologically plausible lead than the osteoarthritis signal and may warrant separate tracking.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23519823 | 2013 | Cohort | International Orthopaedics | High-dose daptomycin + rifampicin for Gram-positive osteoarticular infections — evaluated safety/efficacy of the combination, not OA treatment |
| 22511636 | 2012 | Cohort | J Antimicrob Chemother | Daptomycin for knee/hip periprosthetic joint infections (PJI) |
| 26235888 | 2015 | Cohort | Int J Antimicrob Agents | High-dose daptomycin (>6 mg/kg) for complicated bone/joint and implant-associated Gram-positive infections |
| 17999973 | 2008 | Cohort | J Antimicrob Chemother | Daptomycin vs. standard therapy for osteoarticular infections associated with S. aureus bacteraemia |
| 21477701 | 2010 | Registry/Cohort | Medicina Clínica | EU-CORE registry: daptomycin use experience across Spanish hospitals for Gram-positive infections |
| 23312602 | 2013 | Cohort/Survey | Int J Antimicrob Agents | Survey of current PJI management practices among infectious disease physicians |
| 22854340 | 2012 | In-vitro susceptibility | Journal of Antibiotics | S. aureus/S. epidermidis susceptibility testing in PJI isolates |
| 25650692 | 2015 | Microbiologic survey | Surgical Infections | 10-year evolution of Staphylococcal susceptibility profiles in osteoarticular infections |
| 32206362 | 2020 | Case Report | Case Reports in Orthopedics | Corynebacterium striatum septic arthritis in a patient originally referred for total knee arthroplasty for OA |
| 41853106 | 2026 | Case Report | ASM Case Reports | Corynebacterium propinquum septic arthritis, first synovial fluid isolation in a native joint |
Note: None of these publications studies daptomycin as a treatment for osteoarthritis itself — all concern management of bacterial infections in or around joints (often in OA patients post-arthroplasty).
Finland Market Information
Daptomycin is not marketed in Finland — no marketing authorizations are currently registered for this product in this dataset.
Safety Considerations
Please refer to the package insert for safety information.
Additional literature-derived safety signal (not from the structured safety dataset, but surfaced during evidence review): one case report (PMID 36693494, 2023) describes daptomycin-induced rhabdomyolysis complicated by acute gouty arthritis, consistent with daptomycin's known association with creatine kinase elevation/myopathy. This is a recognized class effect worth flagging for any future clinical use, independent of the repurposing question.
Conclusion and Next Steps
Decision: Hold
Rationale: The osteoarthritis signal is not supported by genuine mechanistic or clinical evidence — all ten retrieved publications concern treatment of bacterial osteoarticular/prosthetic joint infections, not osteoarthritis itself, and appear to be a keyword co-occurrence artifact rather than a real repurposing opportunity (evidence level L4, decision stage S0, per source scoring).
To proceed, the following is needed:
- Confirm whether TxGNN's osteoarthritis prediction should be deprioritized/excluded given the confounded evidence base
- If pursuing a joint-related signal at all, redirect attention to rheumatoid arthritis (rank 2), where 2025 preclinical data (PMID 39571268, PMID 40923559) show a plausible independent anti-inflammatory mechanism — though this still requires human-stage validation before advancing past S1
- Daptomycin's mechanism of action (MOA) data and TFDA/EMA label warnings and contraindications (currently marked Blocking/High severity data gaps) must be obtained before any safety pre-assessment (S1) can proceed
- Given the drug is not marketed in Finland, market-access and regulatory pathway feasibility would also need to be assessed separately
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.